BLOOD SUPEROXIDE DISMUTASE ACTIVITY IN
PATIENTS WITH KNEE OSTEOARTHRITIS
TREATED WITH OXICAMS
DENISA-CONSTANTINA AMZOIU1#, CĂTĂLINA PISOSCHI2*#,
CAMELIA STĂNCIULESCU2#, MARINELA BEZNĂ3#, FLORICA
POPESCU4#, GABRIELA RĂU5#
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy
2Department of Biochemistry, Faculty of Pharmacy
3Department of Internal Medicine, Faculty of Medicine
4Department of Pharmacology, Faculty of Pharmacy
5Department of Organic Chemistry, Faculty of Pharmacy
University of Medicine and Pharmacy of Craiova 2–4 Petru Rareş Street,
200349 Craiova, Romania
* corresponding author: c_pisoschi@yahoo.com
# All authors had equal contributions to this study
Download Full Article

Abstract:

The aim of this study was to compare the effects of three non-steroidal antiinflammatory drugs (NSAIDs) belonging to the oxicam class: piroxicam and tenoxicam, as nonselective inhibitors of cyclooxygenase (COX), and meloxicam, a selective COX-2 inhibitor, on superoxide dismutase (SOD) activity in patients with knee osteoarthritis.
Thirty adult patients clinically and radiographically diagnosed with knee osteoarthritis previously untreated were enrolled and divided in three groups. The serum levels of SOD were assessed at baseline and after 20 days of treatment with: piroxicam at a dose of 20 mg p.o. daily, tenoxicam at a dose of 20 mg p.o. daily, and meloxicam 15 mg p.o. daily.
Piroxicam treated group had a significant increase in SOD activity (p = 0.04), meloxicam treated group had no significant change in SOD activity (p = 0.11), whereas tenoxicam treated group had unchanged SOD activity (p = 0.85). The study of the effects of 20 days treatment with NSAIDs belonging to oxicam group in patients with knee osteoarthritis revealed that piroxicam significantly increase SOD activity.

Top